Zura Bio Limited

Equities

ZURA

KYG9TY5A1016

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 23:00:00 17/06/2024 BST			5-day change	1st Jan Change
3.38 ^USD	-9.38%		-10.34%	-27.62%

06-14	Zura Bio Presents Data for the Tibulizumab (Zb-106) Program At Eular 2024	CI
06-06	Zura Bio Limited Announces Formation of a Scientific Advisory Board	CI

Zura Bio Limited to Present Data Exploring the Expanded Potential of Tibulizumab Into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

June 03, 2024 at 11:00 am

Zura Bio Limited announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna. Zura Bio will present results as detailed below. The poster will be available on the Zura Bio website in the News and Events section and archived for at least 30 days following presentation.

Resolving Inflammation in a Murine Model of Arthritis Through the Dual Antagonism of B-Cell Activating Factor (BAFF) and IL-17.

Latest news about Zura Bio Limited

Zura Bio Presents Data for the Tibulizumab (Zb-106) Program At Eular 2024	06-14	CI
Zura Bio Limited Announces Formation of a Scientific Advisory Board	06-06	CI
Zura Bio Limited to Present Data Exploring the Expanded Potential of Tibulizumab Into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024	06-03	CI
Zura Bio Insider Bought Shares Worth $496,000, According to a Recent SEC Filing	05-23	MT
Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating	05-10	MT
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Zura Bio Limited announced that it has received $112.4935 million in funding from a group of investors	05-05	CI
Piper Sandler Starts Zura Bio With Overweight Rating, $26 Price Target	05-03	MT
Zura Bio Insider Bought Shares Worth $499,999, According to a Recent SEC Filing	04-25	MT
Zura Bio Insider Bought Shares Worth $3,715,000, According to a Recent SEC Filing	04-25	MT
Zura Bio Expects To Raise About $112.5 Million in Gross Proceeds From Oversubscribed Private Placement	04-18	MT
Zura Bio Limited announced that it expects to receive $112.4935 million in funding from a group of investors	04-17	CI
Sector Update: Health Care Stocks Softer Monday Afternoon	04-08	MT
Zura Bio Shares Rise After Robert Lisicki Assumes CEO Role	04-08	MT
Oppenheimer Adjusts Zura Bio Price Target to $16 From $17, Maintains Outperform Rating	04-01	MT
Zura Bio Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Zura Bio Limited Appoints Announces Chief Executive Officer Changes	03-28	CI
Zura Bio Limited Appoints Lisicki as A Director of the Board	03-28	CI
Zura Bio Limited Announces Executive Appointments	01-08	CI
Zura Bio Insider Sold Shares Worth $8,000,000, According to a Recent SEC Filing	12-14	MT
Zura Bio Limited Appoints Kiran Nistala as Executive Vice President	12-06	CI
Zura Bio Announces Two Immunology Abstracts Presented At the World Allergy Congress in Bangkok	12-04	CI
Zura Bio Limited Announces Board Changes	11-14	CI
Zura Bio Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Ladenburg Thalmann Starts Zura Bio With Buy Rating, $10 Price Target	10/10/23	MT

Chart Zura Bio Limited

Duration

Period

More charts

Company Profile

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Sector

Biotechnology & Medical Research

Calendar

23/06/2024 - Oppenheimer Novel Targets in Immunology Summit

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.42 USD

Average target price

17.8 USD

Spread / Average Target

+420.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZURA BIO LIMITED	-27.62%	213M
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-16.19%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B
INSMED INCORPORATED	+119.39%	10.96B

Bio Therapeutic Drugs